Investor News / RNS

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it will be posting its interim results on Thursday 7 March 2024.   The Company will provide a live presentation update in-line with these results via Investor Meet Company on 18 March 2024 at 12:00 pm GMT. During this presentation,...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been chosen by The University of Sheffield (the “University”) to support a grant funded project focused on an insect (Fruit fly) model of cancer treatment.  The value of this work to Physiomics will be £45k and...

Read More

Physiomics plc (AIM: PYC), announces an award of share options (the “Options”) over ordinary shares of 0.4p each in the Company (“Ordinary Shares”).  The Company considers that it is important to incentivise its key executives to create shareholder value and, as such, today the Board has approved the award of the following options to Dr Peter Sargent under the Company’s existing share option scheme (the...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update on the Board changes via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: www.physiomics.co.uk/portfolio-item/investor-presentation-board-changes     Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive Chairman, +44 (0)1235 841575 Dr...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, will provide a brief update on the Board changes via Investor Meet Company on 29 January 2024 at 1:00 pm GMT. During this presentation, Jim Millen Non-Executive Chairman and Peter Sargent CEO would be happy to take questions relating to the changes announced...

Read More

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, announces changes to its board of directors. The Company is pleased to announce that Dr Jim Millen has been appointed Non-Executive Chairman and Dr Peter Sargent, currently Chief Operating Officer, has been appointed as Chief Executive Officer and a director of the Company...

Read More

Physiomics plc (AIM: PYC), an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company’s offices in Oxford, were duly passed.     Enquiries:   Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980   Hybridan LLP (broker) Claire Louise Noyce +44 (0) 203 764 2341   Strand...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling company, supporting development of oncology drugs and personalised medicine solutions, is pleased to announce that it has been awarded a grant by Innovate UK and The Office for Life Sciences as part of the UK Government’s Advancing Precision Medicine programme.  The grant-funded project is called “PREDICT-ONC: Precision Risk Evaluation and G-CSF Dosing for Chemotherapy-Induced Neutropenia Tool” (the...

Read More

Physiomics plc (AIM: PYC), is pleased to announce that, following today’s announcement of a significant grant award from Innovate UK and The Office for Life Sciences to support the Company’s personalised dosing programme, Dr Jim Millen and Dr Pete Sargent will provide a business update via Investor Meet Company on 17 November 2023 at 1:00 pm GMT.   The presentation is open to all existing and potential...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development, announces that, effective today, its registered office has changed to Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.   Enquiries: Physiomics plc Dr Jim Millen, CEO +44 (0)1865 784 980   Hybridan LLP (Broker) Claire Louise Noyce +44 (0) 203 764 2341   Strand Hanson Ltd (NOMAD) James Dance & James Bellman +44 (0)20 7409 3494       Notes to Editor    About Physiomics Physiomics plc combines cutting...

Read More